期刊文献+

急性髓系白血病微小残留病监测的研究进展

原文传递
导出
摘要 急性髓系白血病(AML)是常见的血液系统恶性肿瘤。近年来随着新的化疗药物的出现以及化疗方案的不断完善,急性髓系白血病的无病生存率及总体生存率不断提高,但是仍然要面对缓解后复发这一难题。目前认为复发的主要原因是微小残留病(MRD)的存在,AML的MRD监测对于AML疗效评价,预后预测和指导个体化治疗具有重要意义。近年来MRD的检测方法有了较快发展,如荧光原位杂交(FISH),流式细胞术,PCR技术等。本文将对AML患者MRD监测的方法、监测靶标的选择,及其意义进行论述。其中将重点阐述分子学标志在MRD监测中的应用进展及意义。
出处 《国际输血及血液学杂志》 CAS 2011年第4期337-340,共4页 International Journal of Blood Transfusion and Hematology
基金 国家自然科学基金(30870913)
  • 相关文献

参考文献19

  • 1Raanani P, Ben-Bassat I. Detection of minimal residual disease in acute myelogenous leukemia. Acta Haematol, 2004, 112 ( 1 2) 40-54.
  • 2A1-Mawali A, Gillis D, Lewis 1. The role of muhiparameter flow cytometry for detection of minimal residual disease in acute myeloidleukemia. AmJ ClinPathol,2009,J31(1):16-26.
  • 3Leroy H, de Botton S, Grardel-Duflos N,et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8,21). Leukemia, 2005,19(3) : 367 -372.
  • 4Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML)with favorable cytogenetics [t(8,21) and inv( 16)]. Leukemia, 2006, 20(1) :87-94.
  • 5Lane S, Saal R, Mollee P,et al. A > or=l log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma, 2008,49(33: 517-523.
  • 6Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYHll positive acute myeloidleukemia. J Clin Oncol,2010,28(23):3724-3729.
  • 7Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPMlc, PMI. RARA, RUNX1 RUNX1T1, and CBFB MYHll acute myeloid leukemias. Blood,2010,115(2) : 198-205.
  • 8Gallagher RE, Yeap BY, Bi W,et al. Quantitative real time RT PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in aduh patienls from intergroup protocol 0129. Blood,2003,101(7):2521-2528.
  • 9Santamaria C, Chillon MC, Ferndndez C, et al. Using quantification of the PML RARa transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica,2007, 92(3) :315-322.
  • 10Grimwade D, Jovanovic JV, Hills RK, et al. Prospectivv minimal residual disease monitoring to predicl relapse of acute promyelocytic leukemia and to direct pre emplive arsenic lrioxide therapy. J ClinOncol,2009,27(22):3650-3658.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部